IBDEI162 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20861,1,1,0)
 ;;=1^207.02
 ;;^UTILITY(U,$J,358.3,20861,1,8,0)
 ;;=8^AC Eryth & Erythroleuk in Relapse
 ;;^UTILITY(U,$J,358.3,20861,2)
 ;;=^336481
 ;;^UTILITY(U,$J,358.3,20862,0)
 ;;=207.10^^118^1255^9
 ;;^UTILITY(U,$J,358.3,20862,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20862,1,1,0)
 ;;=1^207.10
 ;;^UTILITY(U,$J,358.3,20862,1,8,0)
 ;;=8^Chr Erythremia w/o Remission
 ;;^UTILITY(U,$J,358.3,20862,2)
 ;;=^336867
 ;;^UTILITY(U,$J,358.3,20863,0)
 ;;=207.11^^118^1255^8
 ;;^UTILITY(U,$J,358.3,20863,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20863,1,1,0)
 ;;=1^207.11
 ;;^UTILITY(U,$J,358.3,20863,1,8,0)
 ;;=8^Chr Erythremia in Remission
 ;;^UTILITY(U,$J,358.3,20863,2)
 ;;=^267558
 ;;^UTILITY(U,$J,358.3,20864,0)
 ;;=207.12^^118^1255^7
 ;;^UTILITY(U,$J,358.3,20864,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20864,1,1,0)
 ;;=1^207.12
 ;;^UTILITY(U,$J,358.3,20864,1,8,0)
 ;;=8^Chr Erythremia in Relapse
 ;;^UTILITY(U,$J,358.3,20864,2)
 ;;=^336482
 ;;^UTILITY(U,$J,358.3,20865,0)
 ;;=207.20^^118^1255^28
 ;;^UTILITY(U,$J,358.3,20865,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20865,1,1,0)
 ;;=1^207.20
 ;;^UTILITY(U,$J,358.3,20865,1,8,0)
 ;;=8^Megakaryocytic Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,20865,2)
 ;;=^336868
 ;;^UTILITY(U,$J,358.3,20866,0)
 ;;=207.21^^118^1255^27
 ;;^UTILITY(U,$J,358.3,20866,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20866,1,1,0)
 ;;=1^207.21
 ;;^UTILITY(U,$J,358.3,20866,1,8,0)
 ;;=8^Megakaryocytic Leuk in Remission
 ;;^UTILITY(U,$J,358.3,20866,2)
 ;;=^267560
 ;;^UTILITY(U,$J,358.3,20867,0)
 ;;=207.22^^118^1255^26
 ;;^UTILITY(U,$J,358.3,20867,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20867,1,1,0)
 ;;=1^207.22
 ;;^UTILITY(U,$J,358.3,20867,1,8,0)
 ;;=8^Megakaryocytic Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,20867,2)
 ;;=^336483
 ;;^UTILITY(U,$J,358.3,20868,0)
 ;;=207.80^^118^1255^47
 ;;^UTILITY(U,$J,358.3,20868,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20868,1,1,0)
 ;;=1^207.80
 ;;^UTILITY(U,$J,358.3,20868,1,8,0)
 ;;=8^Oth Spec Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,20868,2)
 ;;=^336869
 ;;^UTILITY(U,$J,358.3,20869,0)
 ;;=207.81^^118^1255^46
 ;;^UTILITY(U,$J,358.3,20869,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20869,1,1,0)
 ;;=1^207.81
 ;;^UTILITY(U,$J,358.3,20869,1,8,0)
 ;;=8^Oth Spec Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,20869,2)
 ;;=^267562
 ;;^UTILITY(U,$J,358.3,20870,0)
 ;;=207.82^^118^1255^45
 ;;^UTILITY(U,$J,358.3,20870,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20870,1,1,0)
 ;;=1^207.82
 ;;^UTILITY(U,$J,358.3,20870,1,8,0)
 ;;=8^Oth Spec Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,20870,2)
 ;;=^336484
 ;;^UTILITY(U,$J,358.3,20871,0)
 ;;=208.00^^118^1255^21
 ;;^UTILITY(U,$J,358.3,20871,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20871,1,1,0)
 ;;=1^208.00
 ;;^UTILITY(U,$J,358.3,20871,1,8,0)
 ;;=8^Leukemia Unspec w/o Remission
 ;;^UTILITY(U,$J,358.3,20871,2)
 ;;=^336870
 ;;^UTILITY(U,$J,358.3,20872,0)
 ;;=208.01^^118^1255^20
 ;;^UTILITY(U,$J,358.3,20872,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20872,1,1,0)
 ;;=1^208.01
 ;;^UTILITY(U,$J,358.3,20872,1,8,0)
 ;;=8^Leukemia Unspec in Remission
 ;;^UTILITY(U,$J,358.3,20872,2)
 ;;=^267566
 ;;^UTILITY(U,$J,358.3,20873,0)
 ;;=208.02^^118^1255^19
 ;;^UTILITY(U,$J,358.3,20873,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20873,1,1,0)
 ;;=1^208.02
 ;;^UTILITY(U,$J,358.3,20873,1,8,0)
 ;;=8^Leukemia Unspec in Relapse
 ;;^UTILITY(U,$J,358.3,20873,2)
 ;;=^336485
 ;;^UTILITY(U,$J,358.3,20874,0)
 ;;=208.10^^118^1255^12
 ;;^UTILITY(U,$J,358.3,20874,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20874,1,1,0)
 ;;=1^208.10
